Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

HPV Vaccination Is a Battle That Must Be Won

November 2nd 2020

Despite solid evidence that human papillomavirus vaccination is remarkably effective in preventing persistent infection by HPV types that are known to be responsible for more than 70% to 80% of cervical cancer cases worldwide, this strategy’s utility in substantially reducing the subsequent development of the malignancy itself remained an open question.

Shaping a New Future With Novel Therapeutics in Gynecologic Cancers

October 31st 2020

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

Frontline Maintenance Therapy Transforms Advanced Ovarian Cancer With PARP Inhibitors

October 30th 2020

Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.

Two Years of Olaparib Delivers Sustained Remissions in BRCA+ Ovarian Cancer

October 30th 2020

Susana Banerjee, MBBS, MA, PhD, FRCP, discusses the significance of the landmark SOLO-1 analysis and outlined the next steps for research with regard to PARP inhibition in ovarian cancer.

Niraparib Approved in Europe for Frontline Maintenance in Advanced Ovarian Cancer

October 29th 2020

The European Commission has approved niraparib for use as a frontline monotherapy maintenance option in adult patients with advanced epithelial, high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response after platinum-based chemotherapy.

Dr. Jackson on VEGF Versus PARP Inhibitors in Recurrent Ovarian Cancer

October 19th 2020

Amanda L. Jackson, MD, discusses choosing between VEGF inhibitors and PARP inhibitors in the treatment of patients with recurrent platinum-sensitive ovarian cancer.

Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic Malignancies

October 13th 2020

Nicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.

COVID-19 Raises the Stakes of Preventive Medicine in Oncology

October 13th 2020

Anna Giuliano, PhD, discusses the work efforts to advance the reach of preventive vaccines and cancers, and the challenges researchers are facing in the process.

Family History Plays Key Role in Germline Testing for Hereditary Breast and Ovarian Cancers

October 12th 2020

Sofia D. Merajver, MD, PhD, discusses the importance of germline testing in patients with breast and ovarian cancer along with how this testing is being used to personalize treatment.

Discussing Sexual Health Early Holds Benefits for Patients With Cancer

October 8th 2020

Maintaining sexual function is often low on the list of priorities for a woman recently diagnosed with a gynecologic cancer, but raising the subject early in her treatment course may make the patient more willing to engage in a discussion as her care progresses.

Dr. Concin on the Rationale for the LIO-1 Trial in Advanced Gynecologic Malignancies

October 7th 2020

Nicole Concin, MD, discusses the rationale for the phase 1/2 LIO-1 trial in advanced gynecologic malignancies.

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

October 1st 2020

Erika P. Hamilton, MD, highlights initial findings from the ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial Cancer

September 30th 2020

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Gynecologic Oncologists Continue to Pursue Novel Agents, Immunotherapy in Ovarian Cancer

September 30th 2020

Caroline Billingsley, MD, spoke to established and emerging treatment modalities in ovarian cancer and the successes and pitfalls of key clinical trials of antibody-drug conjugates and immunotherapy in this space.

Maintenance PARP Yields Impressive PFS Benefit in Recurrent, Platinum-Sensitive Ovarian Cancer

September 30th 2020

Amanda L. Jackson, MD, , discusses the role of PARP inhibitors in the maintenance treatment of patients with recurrent platinum-sensitive ovarian cancer.

Pivotal Trials Cast PARP Inhibitors into Frontline Maintenance Therapy in Ovarian Cancer

September 30th 2020

Thomas Herzog, MD, discusses the data that have cast PARP inhibitors into the forefront of treatment in the up-front management of patients with advanced ovarian cancer.

Secondary Cytoreduction Plays Role in Recurrent Ovarian Cancer Management, But Selection Is Key

September 29th 2020

Michael Guy, MD, discusses pivotal trials that have helped to define the role of secondary cytoreductive surgery in recurrent ovarian cancer.

Atezolizumab Plus Bevacizumab/Chemo Fails to Significantly Improve PFS in Ovarian Cancer

September 21st 2020

The addition of atezolizumab to a backbone comprised of bevacizumab and chemotherapy failed to significantly improve progression-free survival in patients with newly diagnosed stage III/IV ovarian cancer.

Dr. Coleman on the Clinical Implications of the innovaTV 204 Trial in Cervical Cancer

September 21st 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the clinical implications of the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 trial in women with previously treated recurrent or metastatic cervical cancer.

Tisotumab Vedotin Elicits Encouraging Responses in Recurrent/Metastatic Cervical Cancer

September 21st 2020

Tisotumab vedotin demonstrated an objective response rate of 24% in patients with recurrent and/or metastatic cervical cancer who were previously treated with doublet chemotherapy and bevacizumab, if eligible.